Rubidium: Biochemical, Behavioral, and Metabolic Studies in Humans
Abstract
A growing body of experimental evidence indicates that rubidium possesses unique neurophysiological characteristics in animal systems, suggesting a need for investigating its antidepressant potential in humans. Lithium, an element in the same periodic series, has been used successfully in the treatment of mania. A number of studies have demonstrated that rubidium and lithium have contrasting behavioral, EEG, and biochemical properties. Over a period of 20 to 86 days. five depressed patients received varying doses of rubidium chloride, up to a maximum of 370 mEq. retained. No immediate or long-term side effects were recorded in this preliminary dose range. Behavioral and metabolic data are presented for these patients, along with a discussion of the safety factors.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
